MAG
MRNA icon

Mayfair Advisory Group’s Moderna MRNA Stock Holding History

Mayfair Advisory Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,164
Closed -$231K – 149
2024
Q1 		$231K Buy
2,164
+122
+6% +$12.3K 0.17% 124
2023
Q4 		$230K Hold
2,042
– – 0.2% 112
2023
Q3 		$213K Hold
2,042
– – 0.21% 114
2023
Q2 		$243K Hold
2,042
– – 0.24% 99
2023
Q1 		$321K Buy
2,042
+50
+3% +$8.25K 0.35% 73
2022
Q4 		$366K Buy
1,992
+300
+18% +$49.1K 0.47% 61
2022
Q3 		$205K Hold
1,692
– – 0.29% 104
2022
Q2 		$278K Buy
+1,692
New +$242K 0.37% 83

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Mayfair Advisory Group's MRNA Position: Q2 2024 in Review

Mayfair Advisory Group sold out of Moderna (MRNA) in Q2 2024, closing a stake of 2,164 shares — an estimated $231K sold.

Mayfair Advisory Group first reported a position in MRNA in Q2 2022 and held it in 8 quarters. The position peaked at $366K in Q4 2022. 954 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

  • Mayfair Advisory Group reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
  • Mayfair Advisory Group sold 2,164 Moderna shares in Q2 2024, an estimated $231K.
  • Mayfair Advisory Group first reported a position in Moderna in Q2 2022 and held it in 8 quarters.
  • Mayfair Advisory Group's Moderna position peaked at $366K in Q4 2022.
  • 954 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Mayfair Advisory Group's 13F filing for Q2 2024, filed 22 Jul 2024.